Similarities and differences between embryonic implantation and CTC invasion: Exploring the roles of abortifacients in cancer metastasis chemoprevention.
Cancer metastatic chemoprevention
Circulating tumor cells
Contraceptive
Embryonic implantation
Invasion
Mifepristone
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Jul 2022
05 Jul 2022
Historique:
received:
13
03
2022
revised:
18
04
2022
accepted:
24
04
2022
pubmed:
3
5
2022
medline:
26
5
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
Mifepristone (RU486) is a chemical contraceptive marketed in more than 55 countries and used by hundreds of millions of women worldwide. Current studies reported its uses by both genders for a safe and long-term psychotic depression and particularly for traditional cancer chemotherapy. Here, we investigated the multidisciplinary data from recent large epidemiological chemoprevention studies for long-term use of oral contraceptives to reduce cancer risk, and from the unsuccessful clinical trials of mifepristone used as a post-metastatic anticancer drug, and elucidated the similarities and differences in cellular and molecular processes between embryonic implantation to endometrium and adhesion/invasion of circulating tumor cells (CTCs) to vascular endothelium. The deep analyses provide a stronger scientific basis for repurposing abortifacients for safe and effective cancer metastatic chemoprevention. Initiation of such cancer drug development strategy represents a paradigm shift from traditional post-metastasis treatments to novel pre-metastasis chemoprevention.
Identifiants
pubmed: 35500473
pii: S0223-5234(22)00318-X
doi: 10.1016/j.ejmech.2022.114416
pii:
doi:
Substances chimiques
Abortifacient Agents
0
Antineoplastic Agents
0
Mifepristone
320T6RNW1F
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114416Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.